Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details)

v3.25.1
Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Assets:    
Exarafenib milestone asset (Note 4) $ 3,307 $ 3,214
Investment in equity securities 2,382 3,529
Castle Creek warrants (Note 5) 605  
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,307 3,214
Fair Value, Recurring    
Assets:    
Cash equivalents 84,433 92,671
Exarafenib milestone asset (Note 4) 3,307 3,214
Investment in equity securities 2,382 3,529
Castle Creek warrants (Note 5) 605  
Total financial assets 90,727 99,414
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,307 3,214
Total financial liabilities 3,307 3,214
Fair Value, Recurring | Money market funds    
Assets:    
Cash equivalents 58,759 72,304
Fair Value, Recurring | U.S. treasury bills    
Assets:    
Cash equivalents 25,674 20,367
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 84,433 92,671
Investment in equity securities 2,382 3,529
Total financial assets 86,815 96,200
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Cash equivalents 58,759 72,304
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills    
Assets:    
Cash equivalents 25,674 20,367
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Exarafenib milestone asset (Note 4) 3,307 3,214
Castle Creek warrants (Note 5) 605  
Total financial assets 3,912 3,214
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,307 3,214
Total financial liabilities $ 3,307 $ 3,214